EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Corticotroph Tumour Type Influences Clinical Behaviour in Patients With Nonfunctioning Pituitary Neuroendocrine Tumours

Nasrin Al-Shamkhi iD, Britt Edén Engström, Olafur Gudjonsson, Johan Wikström, Olivera Casar-Borota, Eva Rask iD

Endocrinology, Diabetes & Metabolism · 2026

DOI: 10.1002/edm2.70143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology, Diabetes & Metabolism, 2026. Verfasst von Nasrin Al-Shamkhi und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. Hauptthemen laut MEDLINE: Pituitary Neoplasms, Neuroendocrine Tumors, Adenoma. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Swedish state under the agreement between the Swedish government and the county councils (ALF agreement), The Swedish Cancer Society, Cancerfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study aims to describe whether the clinical behaviour of nonfunctioning pituitary neuroendocrine tumours/nonfunctioning pituitary adenomas (NF‐PitNETs/NFPAs) is affected by pituitary cell lineage differentiation, focusing on patients with silent corticotroph tumours (SCTs) and silent gonadotroph tumours (SGTs).

Methods

Patients ( N = 101) who underwent primary surgery for NF‐PitNETs/NFPAs from August 2014 to March 2020 at Uppsala University Hospital were included. Data on sex, age, MRI, pituitary function and immunohistochemical analysis of anterior pituitary hormone and transcription factor expression, were explored.

Results

Seventy‐three patients had SGTs, and 18 had SCTs. Binary logistic regression revealed that having SCT versus SGT (OR 6.41 (CI: 1.20–34.42), p = 0.03), being older at the time of surgery (OR 1.07 (CI: 1.02–1.12), p = 0.01), and having a larger preoperative tumour volume (OR 1.17 (CI: 1.04–1.32), p = 0.01) were associated with an increased likelihood of postoperative pituitary failure. Patients with preoperative pituitary failure were older at the time of surgery ( p = 0.01) and more often had preoperative elevation of prolactin levels ( p = 0.01) than patients without preoperative pituitary failure. SCT patients were younger at the time of surgery than SGT patients ( p = 0.003), but no significant difference in preoperative tumour volume was detected.

Conclusion

The results indicate that cell lineage differentiation in NF‐PitNETs/NFPAs influences clinical behaviour. Patients with SCTs were younger at the time of surgery, and harbouring a SCT was associated with an increased likelihood of having postoperative pituitary failure. These findings emphasise the importance of routine immunohistochemical analyses of anterior pituitary hormone and transcription factor expression to identify silent corticotroph tumours.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pituitary NeoplasmsNeuroendocrine TumorsAdenomaHumansMaleFemaleMiddle AgedAdultAgedMagnetic Resonance ImagingRetrospective Studies

Stichwörter der Autor:innen

hypopituitarismpituitary neuroendocrine tumourtranscription factors

Autor:innen und Institutionen

  • School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Endocrinology and Mineral Metabolism, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  • Neurosurgery, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  • Neuroradiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
  • Genetics and Pathology, Department of Immunology, Uppsala University, Uppsala, Sweden.
  • Department of Clinical Pathology, Uppsala University Hospital, Uppsala, Sweden.

ORCID-Profile: Nasrin Al-Shamkhi, Eva Rask

Förderung

  • The Swedish state under the agreement between the Swedish government and the county councils (ALF agreement)
  • The Swedish Cancer Society
  • Cancerfonden

Zitieren

APA

Al-Shamkhi, N., Edén Engström, B., Gudjonsson, O., Wikström, J., Casar-Borota, O., & Rask, E. (2026). Corticotroph Tumour Type Influences Clinical Behaviour in Patients With Nonfunctioning Pituitary Neuroendocrine Tumours. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.70143

Vancouver

Al-Shamkhi N, Edén Engström B, Gudjonsson O, Wikström J, Casar-Borota O, Rask E. Corticotroph Tumour Type Influences Clinical Behaviour in Patients With Nonfunctioning Pituitary Neuroendocrine Tumours. Endocrinology, Diabetes & Metabolism. 2026. doi:10.1002/edm2.70143

BibTeX
@article{AlShamkhi2026,
  author = {Al-Shamkhi, Nasrin and Edén Engström, Britt and Gudjonsson, Olafur and Wikström, Johan and Casar-Borota, Olivera and Rask, Eva},
  title = {Corticotroph Tumour Type Influences Clinical Behaviour in Patients With Nonfunctioning Pituitary Neuroendocrine Tumours},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2026},
  doi = {10.1002/edm2.70143}
}
Kostenlos starten →